Cochlear's first-of-its-kind hybrid device gets regulatory approval in US

After the US FDA approved the first-of-its-kind hearing device, Cochlear has launched a new hybrid hearing solution that helps people’s hearing by amplifying low-frequency hearing and restoring access to high-frequency hearing, and will open up new opportunities in the US market.

Cochlear’s Nucleus Hybrid System allows people to get back hearing that they’ve been missing, with the hearing device designed to deliver to patients good quality and clarity of sound in even the most difficult hearing situations, especially in noisy environments.

Upon releasing the news, Cochlear said the hearing device is supported by robust clinical evidence which showed that Nucleus Hybrid System recipients heard on average two times better in both quiet and in noise than with hearing aids. Additionally, those recipients reported a 10 times increase in their overall hearing satisfaction than with hearing aids.

People who are candidates for the technology no longer have to worry about straining to hear with their hearing aids, as the Nucleus Hybrid System will maximise their hearing in all frequencies.

Chris Smith, president of Cochlear America, said, “This innovative new hybrid hearing solution will help people regain the sounds of life that had previously been lost and ultimately empower them to connect with others and live a full life. We look forward to expanding access to hearing and instilling hope in those who may be suffering without an effective solution.”